Philosophy of Care
I firmly believe that my patients, particularly those with cancer, are best managed with a multidisciplinary team approach and that patients, along with their family members, are integral to the decision-making process. I feel extremely fortunate to be a part of our National Cancer Institute-Designated Comprehensive Cancer Center, and to work alongside the dedicated physicians, nurses and other affiliated personnel who make it possible for our patients to have some of the very best care available anywhere in the world. In addition to offering state-of-the-art care and clinical research trials, we have the unique opportunity to discuss patients with lung cancer and other thoracic malignancies before an expert panel of sub-specialists at our "Thoracic Tumor Board." Whether it is to diagnose, treat or palliate lung cancer, it is through our tumor board, or through close consultation with my medical oncology, thoracic surgery, radiation oncology, and thoracic radiology colleagues, that I am able to devise the best strategies for my patients. I know care must be individualized, as no single strategy works for all patients. Perhaps more so than for any other disease, a cancer patient's overall condition, as well as their desires and expectations, play the most important role in this decision-making process.
As an Interventional Pulmonologist, I also care for patients with non-malignant pulmonary disorders including severe persistent asthma, chronic obstructive pulmonary disease (COPD), non-malignant pleural effusions and benign airway strictures that may require advanced diagnostic or therapeutic procedures, normally offered only at tertiary centers such as UC Davis. Again, I feel honored to work with a dedicated group of Interventional Pulmonologists and a highly skilled and compassionate group of nurses and respiratory therapists in our Interventional Pulmonology Laboratory.
Dr. Yoneda's primary outpatient clinical interests are in the diagnosis, staging, and palliation of lung cancer and the thoracic complications associated with lung cancer. In addition, as an Interventional Pulmonologist, he is involved in the treatment of severe persistent asthma, severe emphysema, airway stenosis, and pleural effusions, employing innovative and complex techniques to treat these pulmonary disorders. It is his belief that technological advances in these fields have improved patient comfort and safety while improving outcomes and reducing the length of hospitalizations. While a variety of procedural approaches are available, he believes that no single strategy works for all patients, and care must be individualized.
Dr. Yoneda's clinical research is focused on lung cancer, particularly with regard to the role of interventional pulmonology in the diagnosis, management, and palliation of lung cancer, and the development of interstitial lung disease in lung cancer patients. He also conducts clinical trials in chronic obstructive pulmonary disease (COPD) and asthma. His basic-science research has involved the study of alterations in airway epithelial cells exposed to tobacco smoke and on differential gene expression in lung cancer.
M.D., Northwestern University School of Medicine, Chicago IL 1985
B.S., UC Davis, Davis CA 1978
Internship: Internal Medicine, University of Kansas Medical Center, Kansas City KS 1985-1986
Internal Medicine, University of Kansas, Kansas City KS 1986-1988
Pulmonary and Critical Care, UC Davis, Sacramento CA 1993-1997
American Board of Internal Medicine, 1988
American Board of Internal Medicine, Critical Care Medicine, 1986
American Board of Internal Medicine, Pulmonary Disease, 1998
American Association for Bronchology and Interventional Pulmonology
American College of Chest Physicians
American College of Physicians
American Thoracic Society
International Association for the Study of Lung Cancer
Honors and Awards
UC Davis, B.S. with honors, in Biochemistry, 1978
Select Recent Publications
Tan LD, Yoneda, KY, Louie S, Hogarth DK, Castro M. Bronchial Thermoplasty: A Decade of experience: State of the Art. J Allergy Clin Immunol Pract. 2019;(7):71-80
Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Sciurba FC, Shah PL, Wahidi MM, de Oliveira HG, Morrissey B, Cardoso PFG, Hays S, Majid A, Pastis N Jr, Kopas L, Vollenweider M, McFadden PM, Machuzak M, Hsia DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos DJ; LIBERATE Study Group (Ken Yoneda). A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;(19):1151-1164.
Tan LD, Kenyon N, Yoneda KY, Louie S. Bronchial Thermoplasty: Implementing Best Practice in the Era of Cost Containment. Journal of Asthma and Allergy, 2017(10):225-230.
Ken Y. Yoneda, Judith R. Scranton, Michael A. Cadogan, Vanessa Tassell, Sashi Nadanaciva, Keith D. Wilner, Nicholas S. Stollenwerk. Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. Clinical Lung Cancer, 18(5):472-479.
Javad Alizadeh, Amir A. Zeki, Nima Mirzaei, Sandipan Tewary, Adel Rezaei Moghadam, Aleksandra Glogowska, Pandian Nagakannan, Eftekhar Eftekharpour, Emilia Wiechec, Joseph W. Gordon, Fred. Y. Xu, Jared T. Field, Ken Y. Yoneda, Nicholas J. Kenyon, Mohammad Hashemi, Grant M. Hatch, Sabine Hombach-Klonisch, Thomas Klonisch, Saeid Ghavami. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells. Scientific Reports, 7(44841):1-14.
Sriratanaviriyakul N, Lam F, Morrissey BM, Stollenwerk N, Schivo M, Yoneda KY. Safety and Clinical Utility of Flexible Bronchoscopic Cryoextraction in Patients With Non-neoplasm Tracheobronchial Obstruction: A Retrospective Chart Review. Journal of Bronchology and Interventional Pulmonology, 22(4):288-293.
Najib M. Rahman, DPhil; Justin Pepperell, MD; Sunita Rehal, MSc; Tarek Saba, MD; Augustine Tang, FRCS(C-Th); Nabeel Ali, MD; Alex West, MRCP; Gihan Hettiarachchi, MRCP; Dipak Mukherjee, FRCP; Johnson Samuel, FRCP; Andrew Bentley, MD; Lee Dowson, MRCP; Jonathan Miles, MRCP; C. Frank Ryan, FRCPC; Ken Y. Yoneda, MD; Anoop Chauhan, MD; John P. Corcoran, MRCP; Ioannis Psallidas, Ph.D.; John M. Wrightson, DPhil; Rob Hallifax, MRCP; Helen E. Davies, MD; Y. C. Gary Lee, PhD; Melissa Dobson, BSc; Emma L. Hedley, RGN; Douglas Seaton, MD; Nicky Russell, RGN; Margaret Chapman, RGN; Bethan M. McFadyen, RN; Rachel A. Shaw, BA; Robert J. O. Davies, MD†; Nick A. Maskell, DM; Andrew J. Nunn, MSc; Robert F. Miller, FRCP. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion, The TIME1 Randomized Clinical Trial. Journal of the American Medical Association, 314(24):2641-2653.
Gerard A. Silvestri, M.D., Anil Vachani, M.D., Duncan Whitney, Ph.D., Michael Elashoff, Ph.D., Kate Porta Smith, M.P.H., J. Scott Ferguson, M.D., Ed Parsons, Ph.D., Nandita Mitra, Ph.D., Jerome Brody, M.D., Marc E. Lenburg, Ph.D., and Avrum Spira, M.D., for the AEGIS Study Team, [Ken Y. Yoneda]. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. The New England Journal of Medicine, 373(3):243-251.
Johannes F. Fahrmann, Kyoungmi Kim, Brian C. DeFelice, Sandra L. Taylor, David R. Gandara, Ken Y. Yoneda, David T. Cooke, Oliver Fiehn, Karen Kelly and Suzanne Miyamoto. Investigation of Metabolic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention, 24(11):1716-1723.
Suzanne Miyamoto, Sandra L. Taylor, Dinesh K. Barupal, Ayumu Taguchi, Gert Wohlgemuth, William R. Wikoff, Yoneda, K.Y., David R. Gandara, Samir M. Hanash, Kyoungmi Kim, Oliver Fiehn. Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites, 2015(5):192-210.